Small cell lung cancer and non-small cell lung cancer
Conditions
Interventions
Observation group:None
Sponsors
The Army Specialty Medical Center of the People's Liberation Army of China
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria for cohort A (baseline surgery group): 1) Age 18-60 years old, gender not restricted; 2) Diagnosed with primary lung cancer (NSCLC or SCLC) before surgery; 3) Not receiving neoadjuvant chemotherapy, radiotherapy or immunotherapy; 4) Scheduled for lobectomy or wedge resection; 5) The surgical resection specimen has remaining tissue available for research use after pathological sampling; 6) The study participants gave informed consent and signed the informed consent form. Inclusion criteria for cohort B (neoadjuvant followed by surgery group): 1) Age 18-60 years old, gender not restricted; 2) Pathologically diagnosed as NSCLC; 3) Underwent standard neoadjuvant treatment (chemotherapy ± immunotherapy) before surgery; 4) Postoperative pathology can assess the degree of pathological response (MPR definition: residual viable tumor cells = 10%); 5) The surgical resection specimen has remaining tissue available for research use after pathological sampling; 6) The study participants gave informed consent and signed the informed consent form. Inclusion criteria for cohort C (resistance paired group): 1) Age 18-60 years old, gender not restricted; 2) Lung cancer patients diagnosed by pathology (predominantly NSCLC), receiving targeted therapy (such as EGFR-TKI, ALK-TKI, etc.) or immune checkpoint inhibitor therapy; 3) The disease progressed as confirmed by imaging assessment during the treatment; 4) Available tissue specimens before baseline treatment (surgery, biopsy, or archived paraffin specimens) are available; 5) Tumor tissue specimens can be obtained through biopsy or surgery when resistance progresses; 6) The study participants gave informed consent and signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1) Metastatic lung cancer or pulmonary metastases (except for cohort C, which allows local progression or distant metastasis); 2) Combined with other active malignant tumors; 3) Combined with severe infectious diseases (such as HIV, active tuberculosis, etc.); 4) The surgical specimens are insufficient to meet the requirements of clinical pathological diagnosis; 5) The patient or their family members refuse to participate;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Major pathological response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease progression; | — |
Countries
China
Contacts
Public ContactLi Li
The Army Specialty Medical Center of the People's Liberation Army of China
Outcome results
None listed